First Time Loading...

Eliem Therapeutics Inc
NASDAQ:ELYM

Watchlist Manager
Eliem Therapeutics Inc Logo
Eliem Therapeutics Inc
NASDAQ:ELYM
Watchlist
Price: 10.155 USD 21.04% Market Closed
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

ELYM Price Targets Summary
Eliem Therapeutics Inc

Wall Street analysts forecast ELYM stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ELYM is 4.5 USD .

ELYM Lowest Forecast
Wall Street Target
Not Available
ELYM Average Forecast
Wall Street Target
4.5 USD
56% Downside
ELYM Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
4.5 USD
56% Downside
Highest
Price Target
Not Available

ELYM Last Price Targets
Eliem Therapeutics Inc

The latest public price target was made on Apr 26, 2022 by Unknown Analyst from Leerink Partners , who expects ELYM stock to rise by 28% over the next 12 months. You can read more about this price target by viewing the article on Benzinga.

Analyst Price Target Date Article
Unknown Analyst
Leerink Partners
13 USD
Upside 28%
2 years ago
Apr 26, 2022
SVB Leerink Maintains Outperform on Eliem Therapeutics, Lowers Price Target to $13
Benzinga
Unknown Analyst
Leerink Partners
Price Target 13 USD
Upside/Downside 28%
View Source
Eliem Therapeutics Inc Competitors:
Price Targets
IMTX
Immatics NV
78% Upside
4978
ReproCell Inc
94% Upside
301047
Sino Biological Inc
44% Upside
TLX
Telix Pharmaceuticals Ltd
4% Upside
IMTX
Immatics NV
78% Upside
4978
ReproCell Inc
94% Upside
301047
Sino Biological Inc
44% Upside
TLX
Telix Pharmaceuticals Ltd
4% Upside
VCYT
Veracyte Inc
53% Upside
AURA
Aura Biosciences Inc
156% Upside
4597
Solasia Pharma KK
221% Upside
IOVA
Iovance Biotherapeutics Inc
91% Upside

Revenue
Forecast

Revenue Estimate
Eliem Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Eliem Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-18%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Eliem Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

See Also

Summary
ELYM intrinsic value, competitors valuation, and company profile.
DCF Valuation
ELYM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ELYM stock valuation using valuation multiples.
Wall Street Estimates
ELYM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ELYM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ELYM's stock price target?
Price Target
4.5 USD

According to Wall Street analysts, the average 1-year price target for ELYM is 4.5 USD .

ALPHA SPREAD
Join more than 134,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.